ClinicalTrials.gg
CompletedNCT01034137Updated Jul 11, 2016Results posted

A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

A Phase 3 interventional study of methotrexate and placebo MTX in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 21 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-07-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
317
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
28th of 113
317 · median 130
Started
2010
with 8 others
Phase 3
47 of 113
1 open now
Registered
45th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 28th largest by enrollment, is one of 9 that started in 2010, is one of 47 in phase 3, and was the 45th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with early rheumatoid arthritis. Patients will be randomized to receive either tocilizumab (8mg/kg iv every 4 weeks) plus weekly methotrexate (po in ascending doses), or tocilizumab (8mg/kg iv every 4 weeks) plus placebo, or methotrexate plus placebo. Anticipated time on study treatment is 2 years, and target sample size is 300.

Read the detailed description

Multi-center, randomized, double-blind, placebo-controlled (double placebo) three-arm parallel group, comparative study. Patients were randomized in a 1:1:1 ratio to one of the following treatments:

  • TCZ 8 milligram (mg)/kilogram (kg) + MTX (Group I: TCZ+MTX)
  • TCZ 8 mg/kg + placeboMTX (Group II: TCZ+placebo)
  • MTX + placeboTCZ (Group III: MTX+placebo)

Randomization was stratified by participating center and baseline Disease Activity Score, scoring 28 joints (DAS28) level (\<5.1 vs. ≥5.1). Patients were evaluated every 4 weeks and at each visit a decision on dosage changes was made based on efficacy parameters (DAS28) and occurrence of adverse events (AEs). Patients received MTX/placeboMTX in climbing dosages. Hydroxychloroquine (HCQ) was added when remission was not reached with the maximum tolerable dosage (MTD) of MTX/placeboMTX. If after 12 additional weeks remission was not reached, HCQ was stopped and replaced by standard of care therapy (in Group I) or placebo therapy was replaced by the corresponding verum resulting in TCZ+MTX combination therapy (in Groups II and III). In case remission was reached, MTX/placeboMTX and TCZ/placeboTCZ had to be decreased. Patients were followed for a maximum of 24 months

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Treat-to-target, tight control, strategy study, TCZ, MTX
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >/=18 years of age
  • early rheumatoid arthritis (disease symptoms \<1 year) according to ACR criteria
  • disease activity DAS28 >2.6
  • body weight \</=110kg, \</=36

Exclusion criteria

Exclusion Criteria:

  • rheumatic disease other than RA
  • current inflammatory joint disease other than RA
  • previous treatment with any DMARD or biologic drug used in the treatment of RA
  • intra-articular, parenteral or oral used for the arthritis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
317 participants (actual)

Study arms

  • Experimental
    Tocilizumab + Methotrexate

    Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.

    Drug: methotrexate · Drug: tocilizumab [RoActemra/Actemra]

  • Active comparator
    Tocilizumab + Placebo Methotrexate

    Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.

    Drug: placebo MTX · Drug: tocilizumab [RoActemra/Actemra]

  • Active comparator
    Methotrexate + Placebo Tocilizumab

    Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.

    Drug: methotrexate · Drug: placebo TCZ

Interventions

  • orally weekly in ascending dosages, starting at 10mg/week

  • Drugplacebo MTX

    orally weekly

  • Drugplacebo TCZ

    iv every 4 weeks

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    8mg/kg iv every 4 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Sustained Remission Rate At Week 104

    Sustained remission rate (SRR) is defined as Disease Activity Score 28 (DAS28) \<2.6 during ≥ 23 weeks and no more than 4 swollen joints (28 joint count) due to RA at Week 24 of remission, with the exception of up to 2 in-between DAS28 values which could be between 2.6 and 3.2. The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission.

    Time frame: Week 104

Secondary outcomes

  1. Median Time to First Sustained Remission

    It is the time to event analysis for the first period of sustained remission. Sustained remission is defined as DAS28 \<2.6 during ≥23 weeks and no more than 4 swollen joints (28 joint count) due to RA at Week 24 of remission, with the exception of up to 2 in-between DAS28 values which could be between 2.6 and 3.2. The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts (range 0-28), acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission.

    Time frame: Up to Week 104

  2. Mean Duration of First Sustained Remission

    It is the duration of the first period of sustained DAS28 remission. Participants who switch treatment strategy before reaching sustained remission considered failures.

    Time frame: Up to Week 104

  3. Number of Participants Achieving Disease Activity Score 28 Remission at Weeks 12, 24, 52, and 104

    The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission. Participants with missing data at visits before early study termination or who stopped the study prematurely because of insufficient therapeutic response or safety reasons considered non-responders or who stopped the study for other reasons, response set to missing after early withdrawal.

    Time frame: Weeks 12, 24, 52, and 104

  4. Median Time to First Disease Activity Score 28 Remission

    It is the time to event analysis for the first DAS28 remission.

    Time frame: Up to Week 104

  5. Percentage of Participants With Cumulative Remission Rate at Weeks 12, 24, 52, and 104

    The DAS28 score is a measure of the subject's disease activity. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. Participants with missing data at visits before early study termination or who stopped the study prematurely because of insufficient therapeutic response or safety reasons considered non-responders or who stopped the study for other reasons, response set to missing after early withdrawal.

    Time frame: Weeks 12, 24, 52, and 104

  6. Mean Duration of First Disease Activity Score 28 Remission

    It is the duration of the first period of DAS28 remission.

    Time frame: Up to Week 104

  7. Absolute Change From Baseline in Disease Activity Score 28 at Weeks 12, 24, 52, and 104

    The DAS28 score is a measure of the participant's disease activity. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. Participants with missing data at visits before early study termination or who stopped the study prematurely because of insufficient therapeutic response or safety reasons considered non-responders or who stopped the study for other reasons, response set to missing after early withdrawal.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  8. Median Change From Baseline in Clinical Disease Activity Index Score at Weeks 24, 52, and 104

    The clinical disease activity index (CDAI) are continuous measures of RA disease activity. The CDAI is the numerical sum of four outcome parameters: tender joint count (TJC), swollen joint count (SJC) based on a 28-joint assessment; and patient's global assessment (PtGA) and physician's global assessment (PhGA) assessed on 0-10 cm visual analog scale (VAS). CDAI total score ranges from 0 to 76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.

    Time frame: From Baseline (Week 0) to Weeks 24, 52, and 104

  9. Median Change From Baseline in Simplified Disease Activity Index Scores at Weeks 24, 52, and 104

    The simplified disease activity index (SDAI ) are continuous measures of RA disease activity.The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (assessed on 0-10 cm VAS), and C-Reactive Protein (CRP) (mg/dL). SDAI total score ranges from 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

    Time frame: From Baseline (Week 0) to Weeks 24, 52, and 104

  10. Number of Participants With Good European League Against Rheumatism Response Rate at Weeks 24, 52, and 104

    European league against rheumatism (EULAR) response criteria classify each participant as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual participant's DAS28 as the measure of severity of disease. Good or moderate response is defined as follows: Good response : DAS28 at the time point =\<3.2 and improvement from baseline \> 1.2. Moderate response : DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and =\<1.2.

    Time frame: Weeks 24, 52, and 104

  11. Median Time to First European League Against Rheumatism Response

    It is the time to first EULAR response. EULAR response criteria classify each participant as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual participant's DAS28 as the measure of severity of disease.Good or moderate response is defined as follows: Good response : DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2. Moderate response : DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and ≤ 1.2. Response 1 is defined as yes (good) versus no (moderate or no response). Response 2 is defined as yes (good or moderate) versus no (no response).

    Time frame: Up to Week 104

  12. Percentage of Participants With American College of Rheumatology 20 Response Rate at Weeks 12, 24, 52 and 104

    American College of Rheumatology (ACR) 20 response is defined as a \>= 20% improvement (reduction) compared with baseline for both tender joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: patient's assessment of pain over the previous 24 hours: using a Visual Analog Scale (VAS) with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or Erythrocyte Sedimentation Rate.

    Time frame: Weeks 12, 24, 52 and 104

  13. Percentage of Participants With American College of Rheumatology 50 Response Rate at Weeks 12, 24, 52 and 104

    ACR50 response is defined as a \>=50% improvement (reduction) compared with baseline for both TJC68 and SJC66, as well as for three of the additional five ACR core set variables: patient's assessment of pain over the previous 24 hours: using a VAS with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's Global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or Erythrocyte Sedimentation Rate.

    Time frame: Weeks 12, 24, 52 and 104

  14. Percentage of Participants With American College of Rheumatology 70 Response Rate at Weeks 12, 24, 52 and 104

    ACR70 response is defined as a \>=70% improvement (reduction) compared with baseline for both TJC68 and SJC66, as well as for three of the additional five ACR core set variables: patient's Assessment of pain over the previous 24 hours: using a VAS with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; health assessment questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or Erythrocyte Sedimentation Rate.

    Time frame: Weeks 12, 24, 52 and 104

  15. Percentage of Participants With American College of Rheumatology 90 Response Rate at Weeks 12, 24, 52 and 104

    ACR90 response is defined as a \>=90% improvement (reduction) compared with baseline for both tender joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; health assessment questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or erythrocyte sedimentation rate.

    Time frame: Weeks 12, 24, 52 and 104

  16. Mean Percent Change From Baseline in the Swollen Joint Count (SJC) at Weeks 12, 24, 52, and 104

    The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  17. Mean Percent Change From Baseline in the Tender Joint Count (TJC) at Weeks 12, 24, 52, and 104

    The number of tender joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender joints) to 44 (worse possible score; all tender joints).

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  18. Mean Percent Change From Baseline in Patient Health Visual Analog Scale at Weeks 12, 24, 52, and 104

    Patient health visual analog scale is a component of ACR. It is measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity). An improvement (decrease) in the patient's global assessment based on disease activity relative to respective baseline values was analyzed.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  19. Mean Percent Change From Baseline in The Physician Health Visual Analog Scale at Weeks 12, 24, 52, and 104

    Physician health visual analog scale is a component of ACR. It is measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity).An improvement (decrease) in the physician's global assessment based on disease activity parameter relative to respective baseline values was analyzed.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  20. Mean Percent Change From Baseline in Pain Visual Analog Scale at Weeks 12, 24, 52, and 104

    Pain VAS is a component of ACR. VAS pain score calculated as 0 to 10 cm; where 0 = no pain, and 10 = worst possible pain.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  21. Mean Percent Change From Baseline in CRP at Weeks 12, 24, 52, and 104

    CRP is a component of ACR. CRP is a marker of inflammation.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52, and 104

  22. Mean Change From Baseline in Modified Sharp/Van Der Heijde Score at Weeks 52 and 104

    The degree of joint damage was assessed using the van der Heijde modified total Sharp score (mTSS). The methodology quantifies the extent of bone erosions for 44 joints and joint space narrowing (JSN) for 42 joints, with higher scores representing greater damage. The independent read of X-ray images was performed by 2 primary readers. In case of discrepancy between the 2 primary readers, an adjudicator was involved. The mTSS can range from 0 to 448 with a higher score indicating more joint damage. A negative change score indicates improvement.

    Time frame: From Baseline (Week 0) to Weeks 52 and 104

  23. Percentage of Participants Who Withdraw Due to Lack of Sufficient Therapeutic Response

    Insufficient therapeutic response (participants not responding to the drug as assessed by the physician) was selected by the investigator as a reason for the participant to withdraw from the study.

    Time frame: Up to Week 104

  24. Number of Participants With Change in The Therapy Strategy During The Study

    Participants who switched treatment strategy from monotherapy (TCZ+ placebo MTX or MTX+ placebo TCZ treatment) to combination therapy (TCZ+MTX treatment) was reported. Also, participants who switched from verum therapy to standard of care was reported in the below table.

    Time frame: From Baseline to Week 104

  25. Mean Change From Baseline in The Dutch Consensus Health Assessment Questionnaire of Quality of Life at Weeks 12, 24, 52, and 104

    The Dutch Consensus Health Assessment Questionnaire (DC-HAQ) disability index is a self-completed participant questionnaire with 8 domains specific for RA. It assesses a participant functional ability, with scores ranging from 0 (without any difficulty) to 3 (unable to do). A change from baseline of -0.22 is considered to be the minimal clinically important difference.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  26. Mean Change From Baseline in The EuroQol Score of Quality of Life at Weeks 12, 24, 52 and 104

    "EuroQol (EQ-5D) is a standard self-completed participant questionnaire that measures health outcome. The EQ-5D questionnaire consists of 2 parts: 1) EQ-5D with five dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale as 1 = no problems, 2 = some/moderate problems, 3 = extreme problems. The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, where '1' indicating full health and '0' representing dead. The positive values indicate that during the study the health status improved. 2) EQ-VAS on a scale of 0 to 100, where 0 = worst possible health status and 100 = best possible health status."

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  27. Mean Change From Baseline in 36-Item Short Form Health Survey of Quality of Life at Weeks 12, 24, 52, and 104

    The 36-Item Short Form Health Survey (SF-36) is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Summary (PCS) and Mental Component Summary (MCS) measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  28. Mean Change From Baseline in Patient Global Health Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

    Patient global health VAS score ranges from 0 to 100 and a higher score indicates worse QoL. Patient global health VAS is a component of DAS28.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  29. Mean Change From Baseline in Physician Global Health Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

    Physician global health VAS score ranges from 0 to 100 and a higher score indicates worse QoL. Physician global health VAS is a component of DAS28.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  30. Mean Change From Baseline in Patient Pain Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

    Participants assessed their pain using a 0 to 10 horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 and is described as "no pain" and the right-hand extreme equals 10 as "unbearable pain" .The final VAS score will be derived by multiplying the original scores by 10.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  31. Mean Change From Baseline in Patient General Wellbeing Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

    Participants assessed their general wellbeing using a 0 to 10 horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 and is described as " not active at all " and the right-hand extreme equals 10 as " very active " .The final VAS score will be derived by multiplying the original scores by 10.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  32. Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Score of Quality of Life at Weeks 12, 24, 52, and 104

    Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participants response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.

    Time frame: From Baseline (Week 0) to Weeks 12, 24, 52 and 104

  33. Mean Change From Baseline in The Revised Illness Perception Questionnaire (IPQ-R) Score of Quality of Life at Week 12

    The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

    Time frame: From Baseline (Week 0) to Week 12

  34. Mean Change From Baseline in The IPQ-R Score of Quality of Life at Week 24

    The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

    Time frame: From Baseline (Week 0) to Week 24

  35. Mean Change From Baseline in The IPQ-R Score of Quality of Life at Week 52

    The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

    Time frame: From Baseline (Week 0) to Week 52

  36. Mean Change From Baseline in The IPQ-R Score of Quality of Life at Week 104

    The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

    Time frame: From Baseline (Week 0) to Week 104

  37. Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Adverse Events Leading to Discontinuation

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), lifethreatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.

    Time frame: Up to Week 104

  38. Number of Participants With Clinically Significant Laboratory Values at Week 12

    Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

    Time frame: Week 12

  39. Number of Participants With Clinically Significant Laboratory Values at Week 24

    Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

    Time frame: Week 24

  40. Number of Participants With Clinically Significant Laboratory Values at Week 52

    Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

    Time frame: Week 52

  41. Number of Participants With Clinically Significant Laboratory Values at Week 104

    Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

    Time frame: Week 104

07

Results

Posted Jul 11, 2016

Participant flow

A total of 360 participants were screened at 21 centers in the Netherlands from 04 JAN 2010 to 30 JUL 2012.

Participant flow — Overall Study
MilestoneTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Started106103108
Completed788178
Not completed282230
Withdrew: Adverse event9108
Withdrew: Withdrawal by subject433
Withdrew: Lack of efficacy9413
Withdrew: Protocol violation221
Withdrew: Refused treatment or did not cooperate201
Withdrew: Administrative or other234

Outcome measures

PrimaryPercentage of Participants Achieving Sustained Remission Rate At Week 104

Sustained remission rate (SRR) is defined as Disease Activity Score 28 (DAS28) \<2.6 during ≥ 23 weeks and no more than 4 swollen joints (28 joint count) due to RA at Week 24 of remission, with the exception of up to 2 in-between DAS28 values which could be between 2.6 and 3.2. The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission.

Time frame:
Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Sustained Remission Rate At Week 104
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Percentage of Participants Achieving Sustained Remission Rate At Week 10485.883.544.4
Statistical analysis
  • Tocilizumab + Methotrexate vs Methotrexate + Placebo Tocilizumab · Cochran-Mantel-Haenszel · p = < 0.001 · Risk ratio (rr): 1.996 · 95% CI 1.589 to 2.506
  • Tocilizumab + Placebo Methotrexate vs Methotrexate + Placebo Tocilizumab · Cochran-Mantel-Haenszel · p = < 0.001 · Risk ratio (rr): 1.855 · 95% CI 1.481 to 2.323
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo Methotrexate · Cochran-Mantel-Haenszel · p = 0.616 · Risk ratio (rr): 1.030 · 95% CI 0.915 to 1.160
SecondaryMedian Time to First Sustained Remission

It is the time to event analysis for the first period of sustained remission. Sustained remission is defined as DAS28 \<2.6 during ≥23 weeks and no more than 4 swollen joints (28 joint count) due to RA at Week 24 of remission, with the exception of up to 2 in-between DAS28 values which could be between 2.6 and 3.2. The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen and tender joint counts (range 0-28), acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission.

Time frame:
Up to Week 104
Reported as:
Median · days
Median Time to First Sustained Remission
daysTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Median Time to First Sustained Remission69.00 (57.00 to 85.00)89.00 (58.00 to 116.00)NA (243.00 to NA)
SecondaryMean Duration of First Sustained Remission

It is the duration of the first period of sustained DAS28 remission. Participants who switch treatment strategy before reaching sustained remission considered failures.

Time frame:
Up to Week 104
Reported as:
Mean · Weeks
Mean Duration of First Sustained Remission
WeeksTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Mean Duration of First Sustained Remission65.85 ± 26.7065.00 ± 24.7552.90 ± 25.11
SecondaryNumber of Participants Achieving Disease Activity Score 28 Remission at Weeks 12, 24, 52, and 104

The DAS28 is a combined index for measuring disease activity in RA. The index includes swollen (range 0-28) and tender (range 0-28) joint counts, acute phase response (ESR in mm/hr), and general health status (participant global assessment of disease activity using VAS, range 1-100 mm). DAS28, which uses a 28-joint count, is derived from the original DAS, which includes a 44-swollen joint count. The DAS28 scale ranges from 0 to 10, where higher scores indicate worsening. DAS28 \<2.6 equals (=) remission. Participants with missing data at visits before early study termination or who stopped the study prematurely because of insufficient therapeutic response or safety reasons considered non-responders or who stopped the study for other reasons, response set to missing after early withdrawal.

Time frame:
Weeks 12, 24, 52, and 104
Reported as:
Number · Number of participants
Number of Participants Achieving Disease Activity Score 28 Remission at Weeks 12, 24, 52, and 104
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=105, 102, 106766623
Week 24, n=105, 102, 106847742
Week 52, n=100, 99, 103718063
Week 104, n=96, 95, 99716758
SecondaryMedian Time to First Disease Activity Score 28 Remission

It is the time to event analysis for the first DAS28 remission.

Time frame:
Up to Week 104
Reported as:
Median · Days
Median Time to First Disease Activity Score 28 Remission
DaysTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Median Time to First Disease Activity Score 28 Remission56.00 (54.00 to 58.00)57.00 (49.00 to 60.00)167.00 (138.00 to 195.00)
SecondaryPercentage of Participants With Cumulative Remission Rate at Weeks 12, 24, 52, and 104

The DAS28 score is a measure of the subject's disease activity. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. Participants with missing data at visits before early study termination or who stopped the study prematurely because of insufficient therapeutic response or safety reasons considered non-responders or who stopped the study for other reasons, response set to missing after early withdrawal.

Time frame:
Weeks 12, 24, 52, and 104
Reported as:
Number · Percentage of participants
Percentage of Participants With Cumulative Remission Rate at Weeks 12, 24, 52, and 104
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=105,102,10672.464.721.7
Week 24, n=105,102,10680.075.539.6
Week 52, n=100, 99,10371.080.861.2
Week 104, n=96, 95, 9963.570.558.6
SecondaryMean Duration of First Disease Activity Score 28 Remission

It is the duration of the first period of DAS28 remission.

Time frame:
Up to Week 104
Reported as:
Mean · Weeks
Mean Duration of First Disease Activity Score 28 Remission
WeeksTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Mean Duration of First Disease Activity Score 28 Remission42.99 ± 31.7937.01 ± 30.8920.49 ± 23.95
SecondaryAbsolute Change From Baseline in Disease Activity Score 28 at Weeks 12, 24, 52, and 104

The DAS28 score is a measure of the participant's disease activity. DAS28 total scores range from 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. Participants with missing data at visits before early study termination or who stopped the study prematurely because of insufficient therapeutic response or safety reasons considered non-responders or who stopped the study for other reasons, response set to missing after early withdrawal.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Median · Scores on a scale
Absolute Change From Baseline in Disease Activity Score 28 at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 123.1 (-0.21 to 7.34)3.3 (0.37 to 6.76)1.4 (-1.53 to 3.91)
Week 243.6 (0.75 to 7.48)3.6 (0.45 to 7.64)2.1 (-1.67 to 5.11)
Week 523.3 (-1.02 to 7.48)3.4 (0.28 to 7.66)3.3 (-0.74 to 6.13)
Week 1043.3 (-0.73 to 6.07)3.3 (0.1 to 6.8)3.2 (-0.79 to 7.52)
SecondaryMedian Change From Baseline in Clinical Disease Activity Index Score at Weeks 24, 52, and 104

The clinical disease activity index (CDAI) are continuous measures of RA disease activity. The CDAI is the numerical sum of four outcome parameters: tender joint count (TJC), swollen joint count (SJC) based on a 28-joint assessment; and patient's global assessment (PtGA) and physician's global assessment (PhGA) assessed on 0-10 cm visual analog scale (VAS). CDAI total score ranges from 0 to 76. CDAI \<= 2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.

Time frame:
From Baseline (Week 0) to Weeks 24, 52, and 104
Reported as:
Median · Scores on a scale
Median Change From Baseline in Clinical Disease Activity Index Score at Weeks 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 24-20.0 (-66.5 to -1.5)-20.0 (-62.5 to 13)-14.8 (-42 to 13)
Week 52-19.5 (-67 to 3)-21.0 (-62.5 to 2)-18.0 (-47.5 to -0.5)
Week 104-19.0 (-39 to 6)-21.5 (-62.5 to -1)-18.0 (-51 to 12)
SecondaryMedian Change From Baseline in Simplified Disease Activity Index Scores at Weeks 24, 52, and 104

The simplified disease activity index (SDAI ) are continuous measures of RA disease activity.The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (assessed on 0-10 cm VAS), and C-Reactive Protein (CRP) (mg/dL). SDAI total score ranges from 0-86. SDAI \<=3.3 indicates disease remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high disease activity.

Time frame:
From Baseline (Week 0) to Weeks 24, 52, and 104
Reported as:
Median · Scores on a scale
Median Change From Baseline in Simplified Disease Activity Index Scores at Weeks 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 24-31.0 (-282 to 6.4)-32.8 (-290 to 12.1)-21.5 (-186 to 45.5)
Week 52-26.3 (-272.5 to 30)-33.5 (-288 to 1.2)-27.9 (-189 to -1.5)
Week 104-25.6 (-98.9 to 11)-32.8 (-293.5 to 6.5)-28.0 (-188.4 to 14.9)
SecondaryNumber of Participants With Good European League Against Rheumatism Response Rate at Weeks 24, 52, and 104

European league against rheumatism (EULAR) response criteria classify each participant as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual participant's DAS28 as the measure of severity of disease. Good or moderate response is defined as follows: Good response : DAS28 at the time point =\<3.2 and improvement from baseline \> 1.2. Moderate response : DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and =\<1.2.

Time frame:
Weeks 24, 52, and 104
Reported as:
Number · Number of participants
Number of Participants With Good European League Against Rheumatism Response Rate at Weeks 24, 52, and 104
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 24, n=105, 97, 103938450
Week 52, n=100, 96, 99758571
Week 104, n=96, 95, 96637265
SecondaryMedian Time to First European League Against Rheumatism Response

It is the time to first EULAR response. EULAR response criteria classify each participant as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual participant's DAS28 as the measure of severity of disease.Good or moderate response is defined as follows: Good response : DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2. Moderate response : DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and ≤ 1.2. Response 1 is defined as yes (good) versus no (moderate or no response). Response 2 is defined as yes (good or moderate) versus no (no response).

Time frame:
Up to Week 104
Reported as:
Median · Days
Median Time to First European League Against Rheumatism Response
DaysTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
EULAR response 135.5 (29.0 to 58.0)47.0 (29.0 to 60.)132.0 (84.0 to 195.0)
EULAR response 229.0 (28.0 to 30.0)29.0 (27.0 to 31.0)57.0 (29.0 to 85.0)
SecondaryPercentage of Participants With American College of Rheumatology 20 Response Rate at Weeks 12, 24, 52 and 104

American College of Rheumatology (ACR) 20 response is defined as a \>= 20% improvement (reduction) compared with baseline for both tender joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: patient's assessment of pain over the previous 24 hours: using a Visual Analog Scale (VAS) with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or Erythrocyte Sedimentation Rate.

Time frame:
Weeks 12, 24, 52 and 104
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology 20 Response Rate at Weeks 12, 24, 52 and 104
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Weeks 1263.867.641.5
Weeks 2475.275.559.4
Weeks 5274.771.768.9
Weeks 10463.565.360.6
SecondaryPercentage of Participants With American College of Rheumatology 50 Response Rate at Weeks 12, 24, 52 and 104

ACR50 response is defined as a \>=50% improvement (reduction) compared with baseline for both TJC68 and SJC66, as well as for three of the additional five ACR core set variables: patient's assessment of pain over the previous 24 hours: using a VAS with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's Global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or Erythrocyte Sedimentation Rate.

Time frame:
Weeks 12, 24, 52 and 104
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology 50 Response Rate at Weeks 12, 24, 52 and 104
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 1247.644.121.7
Week 2463.858.834.0
Week 5261.658.651.5
Week 10449.054.748.5
SecondaryPercentage of Participants With American College of Rheumatology 70 Response Rate at Weeks 12, 24, 52 and 104

ACR70 response is defined as a \>=70% improvement (reduction) compared with baseline for both TJC68 and SJC66, as well as for three of the additional five ACR core set variables: patient's Assessment of pain over the previous 24 hours: using a VAS with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; health assessment questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or Erythrocyte Sedimentation Rate.

Time frame:
Weeks 12, 24, 52 and 104
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology 70 Response Rate at Weeks 12, 24, 52 and 104
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 1230.523.57.5
Week 2443.837.315.1
Week 5244.444.433.0
Week 10436.538.935.4
SecondaryPercentage of Participants With American College of Rheumatology 90 Response Rate at Weeks 12, 24, 52 and 104

ACR90 response is defined as a \>=90% improvement (reduction) compared with baseline for both tender joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a VAS with left end of the line 0=no pain to right end of the line 100=unbearable pain; patient's global assessment of disease activity and physician's global assessment of disease activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; health assessment questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant, either C-reactive protein or erythrocyte sedimentation rate.

Time frame:
Weeks 12, 24, 52 and 104
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology 90 Response Rate at Weeks 12, 24, 52 and 104
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Weeks 129.53.90.0
Weeks 2418.111.84.7
Weeks 5219.221.26.8
Weeks 10420.820.014.1
SecondaryMean Percent Change From Baseline in the Swollen Joint Count (SJC) at Weeks 12, 24, 52, and 104

The number of swollen joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a swollen joint was scored as 1 and absence as 0. The total SJC was derived by the sum of the scores for a range of SJC from 0 (best possible score; no swollen joints) to 44 (worse possible score; all joints swollen).

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in the Swollen Joint Count (SJC) at Weeks 12, 24, 52, and 104
Percent changeTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=104, 100, 98-69.2 ± 91.1-68.2 ± 45.1-44.9 ± 73.9
Week 24, n=100, 100, 97-91.7 ± 18.5-86.9 ± 24.3-69.3 ± 37.8
Week 52, n=86, 91, 87-93.3 ± 19.6-89.0 ± 24.1-91.3 ± 20.0
Week 104, n=78, 80, 77-85.7 ± 44.7-91.6 ± 31.3-87.9 ± 23.7
SecondaryMean Percent Change From Baseline in the Tender Joint Count (TJC) at Weeks 12, 24, 52, and 104

The number of tender joints among 22 anatomical joints for both the right and left side of the body were assessed by a joint evaluator where the presence of a tender joint was scored as 1 and absence as 0. The total TJC was derived by the sum of the scores for a range of TJC from 0 (best possible score; no tender joints) to 44 (worse possible score; all tender joints).

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in the Tender Joint Count (TJC) at Weeks 12, 24, 52, and 104
Percent changeTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=102, 98, 99-68.0 ± 44.6-53.7 ± 84.1-36.9 ± 65.9
Week 24, n=98, 98, 97-81.9 ± 28.8-66.1 ± 83.8-66.6 ± 34.0
Week 52, n=84, 89, 87-77.8 ± 49.8-80.4 ± 33.1-77.7 ± 33.6
Week 104, n=76, 79, 77-84.5 ± 26.4-82.5 ± 30.7-79.9 ± 31.9
SecondaryMean Percent Change From Baseline in Patient Health Visual Analog Scale at Weeks 12, 24, 52, and 104

Patient health visual analog scale is a component of ACR. It is measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity). An improvement (decrease) in the patient's global assessment based on disease activity relative to respective baseline values was analyzed.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Patient Health Visual Analog Scale at Weeks 12, 24, 52, and 104
Percent changeTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n =96, 97, 97-43.8 ± 75.2-40.8 ± 74.7-25.3 ± 69.0
Week 24, n=92, 96, 93-66.5 ± 36.5-54.8 ± 41.8-41.5 ± 62.4
Week 52, n=79, 82, 84-66.5 ± 37.7-63.4 ± 36.8-58.4 ± 69.6
Week 104, n=72, 72, 72-64.0 ± 39.7-67.4 ± 36.3-64.7 ± 39.2
SecondaryMean Percent Change From Baseline in The Physician Health Visual Analog Scale at Weeks 12, 24, 52, and 104

Physician health visual analog scale is a component of ACR. It is measured using a visual analogue scale with scores ranging from 0 to 100 (higher scores indicate worse disease activity).An improvement (decrease) in the physician's global assessment based on disease activity parameter relative to respective baseline values was analyzed.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in The Physician Health Visual Analog Scale at Weeks 12, 24, 52, and 104
Percent changeTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n =104, 101, 100-41.6 ± 47.2-36.5 ± 42.7-18.2 ± 52.5
Week 24, n =100, 101, 98-61.0 ± 37.7-46.7 ± 40.9-26.1 ± 57.9
Week 52, n =86, 92, 88-56.9 ± 42.8-56.2 ± 45.7-48.2 ± 50.1
Week 104, n =78, 81, 78-63.2 ± 37.0-60.2 ± 38.9-53.9 ± 54.8
SecondaryMean Percent Change From Baseline in Pain Visual Analog Scale at Weeks 12, 24, 52, and 104

Pain VAS is a component of ACR. VAS pain score calculated as 0 to 10 cm; where 0 = no pain, and 10 = worst possible pain.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in Pain Visual Analog Scale at Weeks 12, 24, 52, and 104
Percent changeTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=82, 83, 77-59.3 ± 37.6-55.8 ± 34.7-39.1 ± 43.5
Week 24, n=76, 77, 78-74.9 ± 31.4-70.3 ± 25.4-48.6 ± 52.6
Week 52, n=76, 72, 72-77.0 ± 30.9-72.4 ± 41.1-66.4 ± 35.9
Week 104, n=58, 61, 63-76.5 ± 35.0-78.8 ± 27.7-74.9 ± 27.3
SecondaryMean Percent Change From Baseline in CRP at Weeks 12, 24, 52, and 104

CRP is a component of ACR. CRP is a marker of inflammation.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52, and 104
Reported as:
Mean · Percent change
Mean Percent Change From Baseline in CRP at Weeks 12, 24, 52, and 104
Percent changeTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=103, 101, 100-47.4 ± 216.5-69.8 ± 39.4-28.5 ± 65.9
Week 24, n=99, 101, 98-64.4 ± 72.1-69.1 ± 47.1-16.8 ± 127.7
Week 52, n=85, 92, 88-47.1 ± 107.2-51.9 ± 72.0-52.1 ± 100.4
Week 104, n=77, 81, 78-45.5 ± 105.8-12.7 ± 256.5-46.7 ± 65.5
SecondaryMean Change From Baseline in Modified Sharp/Van Der Heijde Score at Weeks 52 and 104

The degree of joint damage was assessed using the van der Heijde modified total Sharp score (mTSS). The methodology quantifies the extent of bone erosions for 44 joints and joint space narrowing (JSN) for 42 joints, with higher scores representing greater damage. The independent read of X-ray images was performed by 2 primary readers. In case of discrepancy between the 2 primary readers, an adjudicator was involved. The mTSS can range from 0 to 448 with a higher score indicating more joint damage. A negative change score indicates improvement.

Time frame:
From Baseline (Week 0) to Weeks 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Modified Sharp/Van Der Heijde Score at Weeks 52 and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 520.50 ± 1.4950.79 ± 3.2420.96 ± 2.870
Week 1041.18 ± 3.9191.45 ± 4.2721.53 ± 2.421
SecondaryPercentage of Participants Who Withdraw Due to Lack of Sufficient Therapeutic Response

Insufficient therapeutic response (participants not responding to the drug as assessed by the physician) was selected by the investigator as a reason for the participant to withdraw from the study.

Time frame:
Up to Week 104
Reported as:
Number · Percentage of participants
Percentage of Participants Who Withdraw Due to Lack of Sufficient Therapeutic Response
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Percentage of Participants Who Withdraw Due to Lack of Sufficient Therapeutic Response32.118.243.3
SecondaryNumber of Participants With Change in The Therapy Strategy During The Study

Participants who switched treatment strategy from monotherapy (TCZ+ placebo MTX or MTX+ placebo TCZ treatment) to combination therapy (TCZ+MTX treatment) was reported. Also, participants who switched from verum therapy to standard of care was reported in the below table.

Time frame:
From Baseline to Week 104
Reported as:
Number · Number of participants
Number of Participants With Change in The Therapy Strategy During The Study
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Treatment strategy switch01350
Switch from verum to standard of care922
SecondaryMean Change From Baseline in The Dutch Consensus Health Assessment Questionnaire of Quality of Life at Weeks 12, 24, 52, and 104

The Dutch Consensus Health Assessment Questionnaire (DC-HAQ) disability index is a self-completed participant questionnaire with 8 domains specific for RA. It assesses a participant functional ability, with scores ranging from 0 (without any difficulty) to 3 (unable to do). A change from baseline of -0.22 is considered to be the minimal clinically important difference.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in The Dutch Consensus Health Assessment Questionnaire of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=95, 95, 91-0.5 ± 0.6-0.5 ± 0.5-0.2 ± 0.5
Week 24, n=92, 94, 87-0.7 ± 0.6-0.6 ± 0.6-0.4 ± 0.5
Week 52, n=81, 81, 82-0.7 ± 0.7-0.7 ± 0.6-0.5 ± 0.6
Weeks 104, n=68, 75, 71-0.6 ± 0.7-0.6 ± 0.6-0.4 ± 0.6
SecondaryMean Change From Baseline in The EuroQol Score of Quality of Life at Weeks 12, 24, 52 and 104

"EuroQol (EQ-5D) is a standard self-completed participant questionnaire that measures health outcome. The EQ-5D questionnaire consists of 2 parts: 1) EQ-5D with five dimensions: mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each dimension is rated on a 3-point response scale as 1 = no problems, 2 = some/moderate problems, 3 = extreme problems. The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, where '1' indicating full health and '0' representing dead. The positive values indicate that during the study the health status improved. 2) EQ-VAS on a scale of 0 to 100, where 0 = worst possible health status and 100 = best possible health status."

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in The EuroQol Score of Quality of Life at Weeks 12, 24, 52 and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
EQ-5D Week 12, n=72, 72, 780.15 ± 0.250.19 ± 0.250.11 ± 0.28
EQ-VAS Week 12, n=69, 70, 7311.94 ± 21.079.31 ± 16.902.92 ± 17.54
EQ-5D Week 24, n=69, 73, 730.19 ± 0.220.15 ± 0.300.15 ± 0.27
EQ-VAS Week 24, n=67, 69, 7113.15 ± 21.9310.86 ± 21.468.97 ± 20.17
EQ-5D Week 52, n=61, 61, 690.18 ± 0.250.21 ± 0.240.25 ± 0.29
EQ-VAS Week 52, n=58, 59, 6712.52 ± 21.6113.71 ± 18.6313.40 ± 24.45
EQ-5D Week 104, n=50,57,540.14 ± 0.220.20 ± 0.280.21 ± 0.29
EQ-VAS Week 104, n=50,52,5710.88 ± 20.4314.37 ± 20.4910.96 ± 23.06
SecondaryMean Change From Baseline in 36-Item Short Form Health Survey of Quality of Life at Weeks 12, 24, 52, and 104

The 36-Item Short Form Health Survey (SF-36) is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Summary (PCS) and Mental Component Summary (MCS) measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in 36-Item Short Form Health Survey of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
PCS Week 12, n=72, 73, 7911.2 ± 13.414.2 ± 14.06.8 ± 14.1
MCS Week 12, n=72, 71, 76.2 ± 12.310.9 ± 14.13.9 ± 12.7
PCS Week 24, n= 72, 74, 7616.3 ± 15.413.6 ± 16.49.1 ± 15.1
MCS Week 24, n=67, 72,759.5 ± 13.69.3 ± 16.65.7 ± 13.9
PCS Week 52, n=62, 63, 6818.9 ± 16.020.1 ± 17.215.7 ± 17.0
MCS Week 52, n=61, 63, 6910.1 ± 12.913.6 ± 15.810.3 ± 16.6
PCS Week 104, n=52, 57, 6015.2 ± 19.815.1 ± 18.313.9 ± 19.9
MCS Week 104, n=51, 57, 609.4 ± 12.29.7 ± 16.58.6 ± 15.5
SecondaryMean Change From Baseline in Patient Global Health Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

Patient global health VAS score ranges from 0 to 100 and a higher score indicates worse QoL. Patient global health VAS is a component of DAS28.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Patient Global Health Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=101, 99, 103-25.8 ± 25.7-24.2 ± 24.7-14.8 ± 25.4
Week 24, n= 97, 95, 96-33.9 ± 23.5-29.2 ± 26.1-20.4 ± 27.3
Week 52, n=84, 90, 84-34.3 ± 26.1-34.9 ± 26.2-31.5 ± 28.3
Week 104, n=76, 83, 74-33.2 ± 22.1-34.3 ± 27.4-36.2 ± 28.6
SecondaryMean Change From Baseline in Physician Global Health Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

Physician global health VAS score ranges from 0 to 100 and a higher score indicates worse QoL. Physician global health VAS is a component of DAS28.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Physician Global Health Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=79, 82, 79-35.4 ± 23.0-34.6 ± 23.1-23.0 ± 23.1
Week 24, n=74, 75, 78-43.9 ± 25.1-43.8 ± 21.1-31.0 ± 25.7
Week 52, n=71, 71, 71-45.4 ± 24.9-46.9 ± 23.3-37.7 ± 23.5
Week 104, n=61, 68, 64-43.7 ± 26.6-50.7 ± 23.5-41.1 ± 22.2
SecondaryMean Change From Baseline in Patient Pain Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

Participants assessed their pain using a 0 to 10 horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 and is described as "no pain" and the right-hand extreme equals 10 as "unbearable pain" .The final VAS score will be derived by multiplying the original scores by 10.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Patient Pain Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=95, 96, 101-28.7 ± 28.8-29.5 ± 31.0-19.7 ± 25.5
Week 24, n=92, 93, 92-36.4 ± 28.3-33.5 ± 27.4-28.0 ± 26.9
Week 52, n=78, 83, 82-37.9 ± 26.1-36.6 ± 27.2-38.1 ± 27.1
Week 104, n=73, 80, 72-34.0 ± 26.8-36.4 ± 27.0-41.0 ± 24.5
SecondaryMean Change From Baseline in Patient General Wellbeing Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104

Participants assessed their general wellbeing using a 0 to 10 horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 and is described as " not active at all " and the right-hand extreme equals 10 as " very active " .The final VAS score will be derived by multiplying the original scores by 10.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Patient General Wellbeing Visual Analog Scale Score of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=30, 19, 19-27.3 ± 24.2-31.1 ± 27.0-6.6 ± 27.0
Week 24, n=28, 18, 18-36.1 ± 23.7-35.6 ± 34.0-16.1 ± 24.8
Week 52, n=23, 17, 15-40.9 ± 22.5-45.6 ± 25.7-26.0 ± 23.1
Week 104, n=23, 16, 19-31.1 ± 22.4-38.1 ± 31.7-34.7 ± 27.3
SecondaryMean Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Score of Quality of Life at Weeks 12, 24, 52, and 104

Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participants response to the questions (with the exception of 2 negatively stated), the greater the participants fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the participant's health status.

Time frame:
From Baseline (Week 0) to Weeks 12, 24, 52 and 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue Score of Quality of Life at Weeks 12, 24, 52, and 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Week 12, n=98, 98, 994.3 ± 8.96.5 ± 8.93.4 ± 9.5
Week 24, n=98, 99, 947.3 ± 9.36.7 ± 10.64.4 ± 8.5
Week 52, n=84, 86, 856.9 ± 10.67.9 ± 10.46.4 ± 10.1
Week 104, n=74, 78, 746.3 ± 9.75.8 ± 10.57.0 ± 10.7
SecondaryMean Change From Baseline in The Revised Illness Perception Questionnaire (IPQ-R) Score of Quality of Life at Week 12

The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

Time frame:
From Baseline (Week 0) to Week 12
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in The Revised Illness Perception Questionnaire (IPQ-R) Score of Quality of Life at Week 12
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Identity, n=98, 98, 99-0.6 ± 2.0-0.8 ± 1.8-0.1 ± 2.3
Acute or Chronic Timeline, n=95, 97, 92-0.1 ± 0.7-0.0 ± 0.60.0 ± 0.5
Consequences, n=95, 96, 95-0.4 ± 0.7-0.4 ± 0.7-0.2 ± 0.5
Personal Control, n=98, 98, 980.1 ± 0.50.1 ± 0.6-0.1 ± 0.7
Treatment Control, n=98, 96, 940.2 ± 0.50.2 ± 0.50.1 ± 0.5
Illness Coherence, n=95, 96, 950.2 ± 0.70.3 ± 0.70.2 ± 0.7
Timeline Cyclical, n=95, 98, 96-0.2 ± 0.8-0.0 ± 0.7-0.2 ± 0.6
Emotional Representation, n=95, 98, 96-0.4 ± 0.8-0.6 ± 0.9-0.5 ± 0.9
SecondaryMean Change From Baseline in The IPQ-R Score of Quality of Life at Week 24

The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

Time frame:
From Baseline (Week 0) to Week 24
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in The IPQ-R Score of Quality of Life at Week 24
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Identity, n=98, 99, 94-1.2 ± 2.1-1.0 ± 1.9-0.3 ± 2.1
Acute or Chronic Timeline, n=97, 96, 87-0.0 ± 0.70.1 ± 0.60.0 ± 0.6
Consequences, n=97, 96, 89-0.5 ± 0.7-0.4 ± 0.8-0.3 ± 0.7
Personal Control, n=98, 97, 940.1 ± 0.60.0 ± 0.7-0.1 ± 0.8
Treatment Control, n=98, 95, 91,0.1 ± 0.50.1 ± 0.50.2 ± 0.5
Illness Coherence, n=96, 94, 890.3 ± 0.70.3 ± 0.70.2 ± 0.2
Timeline Cyclical, n=96, 97,90-0.3 ± 0.7-0.2 ± 0.8-0.2 ± 0.7
Emotional Representation, n=96, 97, 90-0.5 ± 0.9-0.5 ± 1.0-0.5 ± 1.0
SecondaryMean Change From Baseline in The IPQ-R Score of Quality of Life at Week 52

The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

Time frame:
From Baseline (Week 0) to Week 52
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in The IPQ-R Score of Quality of Life at Week 52
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Identity, n=84, 86, 85-1.0 ± 2.3-1.4 ± 2.5-1.0 ± 2.0
Acute or Chronic Timeline, n=83, 82, 83-0.1 ± 0.90.1 ± 0.70.1 ± 0.6
Consequences, n=83, 82, 84-0.7 ± 0.9-0.7 ± 0.7-0.5 ± 0.7
Personal Control, n=84, 84, 840.1 ± 0.60.1 ± 0.60.0 ± 0.6
Treatment Control, n=84, 84, 840.1 ± 0.60.2 ± 0.60.2 ± 0.5
Illness Coherence, n=83, 80, 830.3 ± 0.70.4 ± 0.70.4 ± 0.7
Timeline Cyclical, n=83, 83, 83-0.2 ± 0.8-0.3 ± 0.8-0.3 ± 0.7
Emotional Representation, n=83, 82, 83-0.7 ± 1.0-0.7 ± 1.1-0.7 ± 1.1
SecondaryMean Change From Baseline in The IPQ-R Score of Quality of Life at Week 104

The IPQ-R includes 9 domains (identity, acute or chronic timeline, consequences, personal and treatment control, illness coherence, timeline cyclical, emotional representations, and cause). For first 8 domains it scores as: 1(strongly disagree), 2(disagree), 3(neither agree/disagree), 4(agree), and 5(strongly agree), except identity as 1(yes) and 0(no). The sum of scores for identity, timeline, consequences, and cyclical domains are ranged from 0-16. High score represent strongly held beliefs about the number of symptoms attributed to RA, the chronicity of the condition, the negative consequences of the illness and the cyclical nature of the condition. The sum of scores for personal and treatment control, coherence dimensions, and emotional representations are ranged from 0-15. High score represent positive beliefs about the number of controllability of RA and a personal understanding of the condition. The data for 'Cause' domain was not considered for analysis in this study.

Time frame:
From Baseline (Week 0) to Week 104
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in The IPQ-R Score of Quality of Life at Week 104
Scores on a scaleTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Identity, n=74, 78, 74-1.0 ± 2.3-1.3 ± 2.1-0.9 ± 2.3
Acute or Chronic Timeline, n=69, 75, 720.0 ± 0.90.3 ± 0.90.3 ± 0.7
Consequences, n=69, 76, 73-0.6 ± 0.8-0.5 ± 0.8-0.5 ± 0.8
Personal Control, n=74, 77, 740.1 ± 0.70.0 ± 0.70.0 ± 0.7
Treatment Control, n=72, 76, 730.1 ± 0.60.1 ± 0.7-0.0 ± 0.7
Illness Coherence, n=69, 75,720.3 ± 0.70.4 ± 0.70.4 ± 0.8
Timeline Cyclical, n=69, 77, 73-0.1 ± 0.7-0.1 ± 0.8-0.1 ± 0.8
Emotional Representation, n=69, 77, 73-0.6 ± 1.0-0.7 ± 1.1-0.7 ± 1.0
SecondaryNumber of Participants With Any Adverse Events, Any Serious Adverse Events, and Adverse Events Leading to Discontinuation

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), lifethreatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above.

Time frame:
Up to Week 104
Reported as:
Number · Number of participants
Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Adverse Events Leading to Discontinuation
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Any AE10599106
Any SAE161913
AEs Leading to Discontinuation231619
SecondaryNumber of Participants With Clinically Significant Laboratory Values at Week 12

Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

Time frame:
Week 12
Reported as:
Number · Number of participants
Number of Participants With Clinically Significant Laboratory Values at Week 12
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Absolute Neutrophil Count, n=97, 94, 97200
Eosinophil, n=93, 90, 93000
Hematocrit, n=104,100,100000
Hemoglobin, n=104, 101,100001
Red blood cells, n=104,100,100100
Thrombocyte, n=104, 101,100000
White blood cells, n=104, 101,100320
Alkaline phosphatase, n=104,101, 99000
Alanine transaminase (ALT), n=104, 101,100422
Aspartate aminotransferase (AST), n=104,100,100111
Creatinine, n=104,101,100100
CRP, n=103,100,100302
High-density lipoprotein (HDL), n=101,100,99101
Low-density lipoprotein (LDL), n=99,97,98522
Total cholesterol, n=102,100,99752
Triglycerides, n=102,100, 99222
SecondaryNumber of Participants With Clinically Significant Laboratory Values at Week 24

Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

Time frame:
Week 24
Reported as:
Number · Number of participants
Number of Participants With Clinically Significant Laboratory Values at Week 24
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Absolute Neutrophil Count, n=96, 97 ,97100
Eosinophil, n=91, 93, 93000
Hematocrit, n=100, 99, 98010
Hemoglobin, n=100, 100, 98011
RBC, n=99, 100, 98010
Thrombocyte, n=100, 100, 98000
WBC, n=100, 101, 98200
Alkaline phosphatase, n=100, 101, 98000
ALT, n=100, 101, 98225
AST, n=100, 101, 98201
Creatinine, n=100, 101, 98000
CRP, n=100, 101, 97002
SecondaryNumber of Participants With Clinically Significant Laboratory Values at Week 52

Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

Time frame:
Week 52
Reported as:
Number · Number of participants
Number of Participants With Clinically Significant Laboratory Values at Week 52
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Absolute Neutrophil Count, n=83, 90, 85000
Eosinophil, n=81, 88, 82004
Hematocrit, n=86, 92, 87001
Hemoglobin, n=86, 92, 88002
RBC, n=86, 91, 87001
Thrombocyte, n=85, 92, 88001
WBC, n=86, 92, 88010
Alkaline phosphatase, n=86, 92, 87000
ALT, n=86, 92, 88007
AST, n=86, 91, 88002
Creatinine, n=86, 92, 88020
CRP, n=86, 91, 87100
SecondaryNumber of Participants With Clinically Significant Laboratory Values at Week 104

Laboratory parameters included hematology, chemistry and lipids. Any treatment-emergent abnormal laboratory result accompanied by clinical symptoms or leading to a change in study medication or requiring a change in concomitant therapy was considered clinically significant. Participants with clinically significant laboratory values are reported in the below table.

Time frame:
Week 104
Reported as:
Number · Number of participants
Number of Participants With Clinically Significant Laboratory Values at Week 104
Number of participantsTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
Absolute Neutrophil Count, n=75, 78, 77001
Eosinophil, n=72, 77, 74000
Hematocrit, n=75, 78, 77101
Hemoglobin, n=78, 80, 78101
RBC, n=76, 79, 77100
Thrombocyte, n=78, 79, 78011
WBC, n=78, 80, 78101
Alkaline phosphatase, n=78, 79, 78000
ALT, n=78, 80, 78002
AST, n=78, 80, 78002
Creatinine, n=78, 79, 78110
CRP, n=78, 80, 78100
HDL, n=76, 76, 72101
LDL, n=74, 74, 72013
Total cholesterol, n=76, 76, 72023
Triglycerides, n=76, 76, 72122

Adverse events

Collected over Up to Week 104. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab + Methotrexate—16/106 (15.1%)105/106 (99.1%)
Tocilizumab + Placebo Methotrexate—19/103 (18.4%)99/103 (96.1%)
Methotrexate + Placebo Tocilizumab—13/108 (12%)106/108 (98.1%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
CholelithiasisHepatobiliary disorders3/1060/1030/108
PneumoniaInfections and infestations0/1062/1032/108
OsteoarthritisMusculoskeletal and connective tissue disorders1/1062/1030/108
Helicobacter gastritisInfections and infestations0/1061/1030/108
OsteomyelitisInfections and infestations0/1061/1030/108
Pelvic infectionInfections and infestations0/1061/1030/108
UrosepsisInfections and infestations0/1061/1030/108
Viral pericarditisInfections and infestations0/1061/1030/108
Myocardial infarctionCardiac disorders1/1061/1030/108
Angina pectorisCardiac disorders0/1061/1030/108
Most frequent other events
Showing 10 of 32
Most frequent other events
EventTocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo Tocilizumab
NauseaGastrointestinal disorders27/10620/10348/108
NasopharyngitisInfections and infestations38/10640/10337/108
FatigueGeneral disorders30/10625/10334/108
Alanine aminotransferase increasedInvestigations25/10616/10328/108
HeadacheNervous system disorders20/10615/10322/108
DiarrhoeaGastrointestinal disorders19/10612/10320/108
InfluenzaInfections and infestations18/10613/10310/108
CoughRespiratory, thoracic and mediastinal disorders14/10610/10318/108
DizzinessNervous system disorders12/10612/10317/108
Mouth ulcerationGastrointestinal disorders15/10612/1035/108

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Tocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo TocilizumabTotal
<=18 years0000
Between 18 and 65 years857987251
>=65 years21242166
Age, Continuous
Age, Continuous(years)Tocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo TocilizumabTotal
Mean53.1 ± 11.855.0 ± 12.952.2 ± 13.753.4 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab + MethotrexateTocilizumab + Placebo MethotrexateMethotrexate + Placebo TocilizumabTotal
Female657869212
Male412539105
08

Study locations

21 sites
  • Alkmaar, 1815 JD, Netherlands
  • Amersfoort, 3818 ES, Netherlands
  • Amsterdam, 1056 AB, Netherlands
  • Apeldoorn, 7300 DS, Netherlands
  • Breda, 4819 EV, Netherlands
  • Den Helder, 1782GZ, Netherlands
  • Emmeloord, 8300 GA, Netherlands
  • Gorinchem, 4204 AA, Netherlands
  • Gouda, 2803 HH, Netherlands
  • Groningen, 9700RB, Netherlands
  • Haarlem, 2035 RC, Netherlands
  • Heerlen, 6419 PC, Netherlands
  • Hilversum, 1213 HX, Netherlands
  • Hoofddorp, 2134 TM, Netherlands
  • Leeuwarden, 8934 AD, Netherlands
  • Leiden, 2333 ZA, Netherlands
  • Nieuwegein, 3430 EM, Netherlands
  • Nijmegen, 6522 JV, Netherlands
  • Sneek, 8601 ZK, Netherlands
  • Utrecht, 3584 CX, Netherlands
  • Woerden, 3447 GN, Netherlands
09

References and documents

Publications

  • Gosselt HR, Verhoeven MMA, de Rotte MCFJ, Pluijm SMF, Muller IB, Jansen G, Tekstra J, Bulatovic-Calasan M, Heil SG, Lafeber FPJG, Hazes JMW, de Jonge R. Validation of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis and Its Clinical Application in Evidencio. Rheumatol Ther. 2020 Dec;7(4):837-850. doi: 10.1007/s40744-020-00230-7. Epub 2020 Sep 14. PubMed 32926395 ↗
  • Teitsma XM, Yang W, Jacobs JWG, Petho-Schramm A, Borm MEA, Harms AC, Hankemeier T, van Laar JM, Bijlsma JWJ, Lafeber FPJG. Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology. Arthritis Res Ther. 2018 Oct 15;20(1):230. doi: 10.1186/s13075-018-1729-2. PubMed 30322408 ↗
  • Teitsma XM, Jacobs JWG, Welsing PMJ, de Jong PHP, Hazes JMW, Weel AEAM, Petho-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. Ann Rheum Dis. 2018 Sep;77(9):1261-1267. doi: 10.1136/annrheumdis-2018-213035. Epub 2018 May 14. PubMed 29760159 ↗
  • Teitsma XM, Jacobs JWG, Welsing PMJ, Petho-Schramm A, Borm MEA, van Laar JM, Lafeber FPJG, Bijlsma JWJ. Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies. Rheumatology (Oxford). 2018 Feb 1;57(2):309-317. doi: 10.1093/rheumatology/kex386. PubMed 29095992 ↗
  • Teitsma XM, Jacobs JWG, Welsing PMJ, Petho-Schramm A, Borm MEA, Hendriks L, Denissen NHAM, van Laar JM, Lafeber FPJG, Bijlsma JWJ. Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. Rheumatology (Oxford). 2017 Dec 1;56(12):2179-2189. doi: 10.1093/rheumatology/kex319. PubMed 29029185 ↗
  • Teitsma XM, Jacobs JWG, Mokry M, Borm MEA, Petho-Schramm A, van Laar JM, Bijlsma JWJ, Lafeber FPJ. Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy. Arthritis Res Ther. 2017 Jul 20;19(1):170. doi: 10.1186/s13075-017-1378-x. PubMed 28728565 ↗
  • Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Petho-Schramm A, Bernasconi C, Borm MEA, Wortel CH, Ter Borg EJ, Jahangier ZN, van der Laan WH, Bruyn GAW, Baudoin P, Wijngaarden S, Vos PAJM, Bos R, Starmans MJF, Griep EN, Griep-Wentink JRM, Allaart CF, Heurkens AHM, Teitsma XM, Tekstra J, Marijnissen ACA, Lafeber FPJ, Jacobs JWG. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016 Jul 23;388(10042):343-355. doi: 10.1016/S0140-6736(16)30363-4. Epub 2016 Jun 7. PubMed 27287832 ↗

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2009
First posted
Dec 17, 2009
Start
Jan 2010
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Jul 11, 2016
Last update
Jul 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01034137
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2009
Start date
Jan 2010
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Jul 11, 2016
Last update
Jul 11, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tocilizumab

Start the discussion